Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?
Stefano Ballestri, Amedeo Lonardo, Paola Loria – 24 March 2011
Reply:
Jin‐Kyu Park, Kyu‐Shik Jeong – 24 March 2011
Liver biopsy interpretation in liver cancer
Charles Balabaud – 24 March 2011
Reply:
René Adam, Eric Vibert, Jean‐Charles Duclos‐Vallee, Didier Samuel – 24 March 2011
What is the role of the receptor for advanced glycation end products–ligand axis in liver injury?
Giuseppina Basta, Teresa Navarra, Paolo De Simone, Serena Del Turco, Amalia Gastaldelli, Franco Filipponi – 24 March 2011 – Multiligand receptor for advanced glycation end products (RAGE) is expressed in a wide variety of tissues, including the liver. Interactions with its ligands lead to cellular activation and thus prolonged inflammation and apoptosis.
A simple trick for optimizing the three‐vein technique outflow anastomosis in piggyback liver transplantation
Umberto Baccarani, Vittorio Cherchi, Anna Rossetto, Dario Lorenzin, Gian Luigi Adani – 24 March 2011
No transfats
Brent A. Neuschwander‐Tetri – 24 March 2011
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
Chanunta Hongthanakorn, Watcharasak Chotiyaputta, Kelly Oberhelman, Robert J. Fontana, Jorge A. Marrero, Tracy Licari, Anna S. F. Lok – 24 March 2011 – Virological breakthrough (VBT) is the first manifestation of antiviral drug resistance during nucleos(t)ide analogue (NUC) treatment of chronic hepatitis B (CHB), but not all VBTs are due to drug resistance. This study sought to determine the incidence of VBT and genotypic resistance (GR) in patients with CHB who were receiving NUCs in clinical practice. Records of patients with CHB who were receiving NUCs were reviewed.
Heme oxygenase‐1–mediated autophagy protects against hepatocyte cell death and hepatic injury from infection/sepsis in mice
Evie H. Carchman, Jayashree Rao, Patricia A. Loughran, Matthew R. Rosengart, Brian S. Zuckerbraun – 24 March 2011 – Adaptive responses to sepsis are necessary to prevent organ failure and death. Cellular signaling responses that limit cell death and structural damage allow a cell to withstand insult from sepsis to prevent irreversible organ dysfunction. One such protective pathway to reduce hepatocellular injury is the up‐regulation of heme oxygenase‐1 (HO‐1) signaling.
Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function
James A. Thomas, Caroline Pope, Davina Wojtacha, Andrew J. Robson, Timothy T. Gordon‐Walker, Stephen Hartland, Prakash Ramachandran, Marielle Van Deemter, David A. Hume, John P. Iredale, Stuart J. Forbes – 23 March 2011 – Clinical studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the mechanisms of benefit remain undefined. Cells of the monocyte‐macrophage lineage have key roles in the development and resolution of liver fibrosis. Therefore, we tested the therapeutic effects of these cells on murine liver fibrosis.